Quick Answer
Avalo Therapeutics, Inc. reported Cash and Equivalents of $15.86 million for fiscal year 2025.
Avalo Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $15.86M | -88.2% |
| 2024 | $134.55M | +1714.5% |
| 2023 | $7.42M | -43.7% |
| 2022 | $13.17M | -75.9% |
| 2021 | $54.59M | +188.5% |
| 2020 | $18.92M | +424.2% |
| 2019 | $3.61M | -66.1% |
| 2018 | $10.65M | +330.6% |
| 2017 | $2.47M | -51.8% |
| 2016 | $5.13M | -75.8% |
| 2015 | $21.16M | +80.2% |
| 2014 | $11.74M | +243.2% |
| 2013 | $3.42M | -64.1% |
| 2012 | $9.52M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $26.96M | -67.1% | -36.2% |
| June 30, 2025 | $42.29M | -54.7% | -66.2% |
| March 31, 2025 | $125.05M | +13.5% | -7.1% |
| December 31, 2024 | $134.55M | +1714.5% | +64.4% |
| September 30, 2024 | $81.86M | +704.1% | -12.4% |
| June 30, 2024 | $93.43M | +1381.3% | -15.2% |
| March 31, 2024 | $110.18M | +560.3% | +1385.9% |
| December 31, 2023 | $7.42M | -43.7% | -27.2% |
- Avalo Therapeutics, Inc. showed a decrease of -88.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, Avalo Therapeutics, Inc.’s cash and equivalents has grown by 66.6% (from $9.52 million to $15.86 million).
- The most recent figure is from Avalo Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: